bioAffinity (BIAF) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-41463
Entity Registrant Name	bioAffinity Technologies, Inc.
Entity Central Index Key	0001712762
Entity Tax Identification Number	46-5211056
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	22211 W. Interstate 10
Entity Address, Address Line Two	Suite 1206
Entity Address, City or Town	San Antonio
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78257
City Area Code	(210)
Local Phone Number	698-5334
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,369,750
Common Stock, Par Value $.007 per share [Member]
Title of 12(b) Security	Common Stock, par value $.007 per share
Trading Symbol	BIAF
Security Exchange Name	NASDAQ
Tradeable Warrants to Purchase Common Stock [Member]
Title of 12(b) Security	Tradeable Warrants to purchase Common Stock
Trading Symbol	BIAFW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,497,938	$ 1,360,638
Accounts and other receivables, net	9,930	1,530
Inventory	5,715
Prepaid and other current assets	541,323	76,065
Total current assets	14,054,906	1,438,233
Deferred offering costs		7,942
Property and equipment, net	1,781	4,633
Other assets	6,000	2,500
Total assets	14,062,687	1,453,308
Current liabilities:
Accounts payable	149,867	230,407
Accrued expenses	474,035	483,501
Accrued interest	25,168	1,121,392
Current portion of Paycheck Protection Program loan		52,074
Loan payable	490,117
Convertible notes payable	325,000	11,152,151
Total current liabilities	1,464,187	13,039,525
Paycheck Protection Program loan, less current portion		160,184
Total liabilities	1,464,187	13,199,709
Commitments and contingencies (See Note 9)
Convertible preferred stock, par value $0.001 per share; 20,000,000 shares authorized; 0 and 5,296,044 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $0 and $5,825,648, at September 30, 2022 and December 31, 2021, respectively		4,044,318
Stockholders’ equity (deficit):
Preferred stock, no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, par value $0.007 per share; 14,285,714 shares authorized; 8,369,750 issued and outstanding at September 30, 2022; and 2,677,140 shares issued and outstanding at December 31, 2021, respectively	58,588	18,740
Additional paid-in capital	47,532,797	12,703,896
Accumulated deficit	(34,992,885)	(28,513,355)
Total stockholders’ equity (deficit)	12,598,500	(15,790,719)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)	$ 14,062,687	$ 1,453,308

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	20,000,000	20,000,000
Convertible preferred stock, shares issued	0	5,296,044
Convertible preferred stock, shares outstanding	0	5,296,044
Convertible preferred stock, aggregate liquidation preference	$ 0	$ 5,825,648
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value	$ 0.007	$ 0.007
Common stock, shares authorized	14,285,714	14,285,714
Common stock, shares issued	8,369,750	2,677,140
Common stock, shares outstanding	8,369,750	2,677,140

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 1,150		$ 2,457
Cost of sales	146		292
Gross profit	1,005		2,165
Operating expenses:
Research and development	319,744	330,772	949,388	877,674
Clinical development	60,941	33,972	141,684	78,241
General and administrative	596,476	161,549	1,298,409	591,155
Total operating expenses	977,161	526,293	2,389,481	1,547,070
Loss from operations	(976,156)	(526,293)	(2,387,316)	(1,547,070)
Other income (expense):
Interest income	3	19	850	24
Interest expense	(889,091)	(135,359)	(2,435,941)	(363,828)
Gain on extinguishment of debt			212,258	239,200
Fair value adjustments on convertible notes payable	(3,053,914)	(852,161)	(1,866,922)	924,099
Net loss before provision for income taxes	(4,919,158)	(1,513,794)	(6,477,071)	(747,575)
Income tax expense	300		2,459	1,950
Net loss	$ (4,919,458)	$ (1,513,794)	$ (6,479,530)	$ (749,525)
Net loss per common share, basic and diluted	$ (1.17)	$ (0.57)	$ (2.03)	$ (0.28)
Weighted average common shares outstanding	4,203,781	2,675,054	3,194,765	2,674,924

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 4,044,318	$ 18,724	$ 7,095,355	$ (22,186,942)	$ (15,072,863)
Beginning balance, shares at Dec. 31, 2020	756,558	2,674,860
Stock-based compensation expense			152,837		152,837
Net income (loss)				764,269	764,269
Ending balance, value at Jun. 30, 2021	$ 4,044,318	$ 18,724	7,248,192	(21,422,673)	(14,155,757)
Ending balance, shares at Jun. 30, 2021	756,558	2,674,860
Beginning balance, value at Dec. 31, 2020	$ 4,044,318	$ 18,724	7,095,355	(22,186,942)	(15,072,863)
Beginning balance, shares at Dec. 31, 2020	756,558	2,674,860
Net income (loss)					$ (749,525)
Exercise of stock options, shares					0
Ending balance, value at Sep. 30, 2021	$ 4,044,318	$ 18,730	7,227,880	(22,936,467)	$ (15,689,857)
Ending balance, shares at Sep. 30, 2021	756,558	2,675,772
Beginning balance, value at Jun. 30, 2021	$ 4,044,318	$ 18,724	7,248,192	(21,422,673)	(14,155,757)
Beginning balance, shares at Jun. 30, 2021	756,558	2,674,860
Stock-based compensation expense		$ 6	(20,312)		(20,306)
Stock-based compensation expense, shares		912
Net income (loss)				(1,513,794)	(1,513,794)
Ending balance, value at Sep. 30, 2021	$ 4,044,318	$ 18,730	7,227,880	(22,936,467)	(15,689,857)
Ending balance, shares at Sep. 30, 2021	756,558	2,675,772
Beginning balance, value at Dec. 31, 2021	$ 4,044,318	$ 18,740	12,703,896	(28,513,355)	(15,790,719)
Beginning balance, shares at Dec. 31, 2021	756,558	2,677,140
Stock-based compensation expense		$ 121	132,611		132,732
Stock-based compensation expense, shares		17,319
Beneficial conversion feature for bridge notes			213,942		213,942
Return of capital from stock split			(185)		(185)
Debt discount for warrants issued			217,973		217,973
Net income (loss)				(1,560,072)	(1,560,072)
Ending balance, value at Jun. 30, 2022		$ 18,861	13,268,237	(30,073,427)	(16,786,329)
Ending balance, shares at Jun. 30, 2022		2,694,459
Beginning balance, value at Dec. 31, 2021	$ 4,044,318	$ 18,740	12,703,896	(28,513,355)	(15,790,719)
Beginning balance, shares at Dec. 31, 2021	756,558	2,677,140
Net income (loss)					(6,479,530)
Exercise of stock options					$ 75,000
Exercise of stock options, shares					64,848
Ending balance, value at Sep. 30, 2022		$ 58,588	47,532,797	(34,992,885)	$ 12,598,500
Ending balance, shares at Sep. 30, 2022		8,369,750
Beginning balance, value at Jun. 30, 2022		$ 18,861	13,268,237	(30,073,427)	(16,786,329)
Beginning balance, shares at Jun. 30, 2022		2,694,459
Stock-based compensation expense		$ 6	79,007		79,013
Stock-based compensation expense, shares		835
Beneficial conversion feature for bridge notes			134,277		134,277
Debt discount for warrants issued			165,723		165,723
Net income (loss)				(4,919,458)	(4,919,458)
Common stock issued upon initial public offering, net of underwriters’ commission and offering costs of $1.8 million		$ 8,978	6,018,436		6,027,414
Common stock issued upon initial public offering, net of underwriters' commission and offering costs of $1.8 million, shares		1,282,600
Common stock issued on conversion of convertible preferred stock	$ (4,044,318)	$ 5,296	4,039,022		4,044,318
Common stock issued on conversion of convertible preferred stock, shares	(756,558)	756,558
Common stock issued on conversion of notes payable		$ 17,738	16,047,594		16,065,332
Common stock issued on conversion of notes payable, shares		2,533,964
Exercise of warrants		$ 7,255	7,706,055		7,713,310
Exercise of warrants, shares		1,036,486
Exercise of stock options		$ 454	74,446		74,900
Exercise of stock options, shares		64,848
Ending balance, value at Sep. 30, 2022		$ 58,588	$ 47,532,797	$ (34,992,885)	$ 12,598,500
Ending balance, shares at Sep. 30, 2022		8,369,750

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Statement of Stockholders' Equity [Abstract]
Underwriting discounts, commissions and offering expenses	$ 1.8	$ 1.8

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (6,479,530)	$ (749,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,852	4,023
Accretion of debt issuance costs	1,972,948
Fair value adjustments on convertible notes payable	1,866,922	(924,099)
Stock-based compensation expense	211,745	132,531
Gain on extinguishment of debt	(212,258)	(239,200)
Changes in operating assets and liabilities:
Accounts and other receivables	(8,400)
Inventory	(5,715)
Prepaid expenses and other assets	(502,177)	(51,760)
Accounts payable	(80,725)	68,100
Accrued expenses	(1,524)	(269)
Accrued interest	465,653	363,661
Net cash used in operating activities	(2,770,209)	(1,396,538)
Cash flows from financing activities
Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses of approximately $1.8 million	6,027,414
Exercise of warrants	7,713,310
Exercise of stock options	74,900
Proceeds from loans payable	555,148	212,258
Payment on loans payable	(31,612)
Proceeds from issuance of convertible notes payable	724,000	1,345,000
Repayment of convertible loan payable	(100,000)
Payment of debt issuance costs	(55,651)
Net cash provided by financing activities	14,907,509	1,557,258
Net increase in cash and cash equivalents	12,137,300	160,720
Cash and cash equivalents at beginning of period	1,360,638	83,108
Cash and cash equivalents at end of period	13,497,938	243,828
Supplemental disclosures of cash flow information:
Income taxes paid in cash	2,459	1,950
Interest expense paid in cash	3,945
Noncash financing activities:
Conversion of convertible preferred stock into common stock	4,044,318
Conversion of convertible notes payable into common stock	16,065,332
Fair value of warrants issued to placement agents	352,250
Beneficial conversion feature for bridge notes	$ 379,665

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Statement of Cash Flows [Abstract]
Underwriting discounts, commissions and offering expenses	$ 1.8	$ 1.8

NATURE OF OPERATIONS, ORGANIZAT

NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION	Note 1. NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION Description of Business bioAffinity Technologies, Inc., a Delaware corporation (the “Company,” “we,” or “our”), addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and for targeted cancer treatment. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Our first diagnostic test, CyPath ® in vitro Organization and Initial Public Offering The Company was formed on March 26, 2014 as a Delaware corporation with its corporate offices located in San Antonio, Texas. On June 15, 2016, the Company formed a wholly-owned subsidiary, OncoSelect ® On September 6, 2022, the Company completed its initial public offering (the “IPO”) of 1,282,600 6.125 Each Unit consists of (i) one share of the Company’s common stock, par value $ 0.007 7.35 7.656 7.8 In connection with the closing of the IPO (the “IPO Closing”), the Company converted 5,296,044 756,558 10.6 2,533,964 In June 2022, the Company completed a 1-for-7 reverse stock split 0.007 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC for interim financial reporting. The condensed consolidated financial statements are unaudited, and in management’s opinion, include all adjustments, including normal recurring adjustments and accruals necessary for a fair presentation of the results for the interim periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2022 or any future period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes included in our final IPO prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the “Securities Act”) on September 2, 2022 (the “Final Prospectus”). In accordance with Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a going concern for at least one year after the date the consolidated financial statements are issued. The Company has incurred significant losses and negative cash flows from operations since inception and expects to continue to incur losses and negative cash flows for the foreseeable future. As a result, the Company had an accumulated deficit of $ 35.0 13.5 96 COVID-19 The rapid global spread of the COVID-19 virus since December 2019 has affected production and sales worldwide, disrupted supply chains across a range of industries, and created significant economic volatility. The impact of COVID-19 on the Company’s operational and financial performance will depend on numerous factors, including the spread, duration, and intensity of the pandemic (including resurgences), the emergence of new viral variants, and the impact of the pandemic on the Company’s customers, employees, clinical trial sites, and vendors. As the COVID-19 pandemic continues to evolve, the ultimate impact of the pandemic on the Company’s operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, additional or modified government actions, and the actions taken to contain COVID-19 or address its impact, among others. Management does not yet know the full extent of potential delays or impacts on the Company, clinical trials, research programs, healthcare systems or the global economy but continues to monitor the situation closely.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the fair value of the Company’s Common Stock used to measure stock-based compensation for options granted to employees and non-employees; the valuation allowance on the Company’s deferred tax assets; and the fair value of the convertible notes payable. Principles of Consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect ® Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company’s equity financings, including its IPO, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the financing. The Company capitalized certain legal, accounting and other third-party fees that were directly related to the Company’s IPO. After the completion of the IPO in September 2022, total deferred offering costs of approximately $ 1.8 8,000 Loss Per Share Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2022 and 2021, as they would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES 2022 2021 As of September 30, 2022 2021 Convertible preferred stock — 756,558 Shares underlying options outstanding 806,392 828,386 Shares underlying warrants outstanding 4,624,952 6,428 Shares underlying convertible notes outstanding 83,373 1,591,372 Anti-dilutive securities 5,514,717 3,182,744 Revenue Recognition Our revenue is generated exclusively from royalties for our first diagnostic test, CyPath ® ® To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. Reclassifications Certain prior year balances have been reclassified to conform to current year presentation. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistency in application. ASU 2019-12 will be effective for public entities for interim and annual periods beginning after December 15, 2020, with early adoption permitted. The Company adopted ASU 2019-12 and concluded there is no impact on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions that are required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring that an entity use the if-converted method and that the effect of potential share settlement be included in diluted earnings per share calculations. The new standard will be effective for fiscal years beginning after December 15, 2023 for smaller reporting companies. The Company has not yet determined the potential impact the adoption may have on our consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS	Note 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets are summarized below: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, 2022 December 31, 2021 Insurance $ 471,270 $ 16,765 Legal and professional 61,219 55,081 Other 8,834 4,219 Total prepaid expenses and other current assets $ 541,323 $ 76,065

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	Note 4. PROPERTY AND EQUIPMENT, NET Property and equipment are summarized below: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Lab equipment $ 242,168 $ 242,168 Computers and software 21,463 21,463 Property and equipment, gross 263,631 263,631 Accumulated depreciation (261,850 ) (258,998 ) Total property and equipment, net $ 1,781 $ 4,633 Depreciation and amortization expense was approximately $ 800 1,200 2,900 4,000

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES	Note 5. ACCRUED EXPENSES Accrued expenses are summarized below: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, 2021 Compensation $ 231,628 $ 277,185 Legal and professional 188,524 166,069 Clinical 49,630 39,482 Other 4,253 765 Total accrued expenses $ 474,035 $ 483,501

LOAN PAYABLE

LOAN PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
LOAN PAYABLE	Note 6. LOAN PAYABLE In March 2021, the Company received a second U.S. Small Business Administration (the “SBA”) Paycheck Protection Program (“PPP”) Loan for $ 0.2 1.0 two years 0.2 In September 2022, the Company obtained short-term financing of approximately $ 0.5 ten monthly payments 42,000 4.3

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	Note 7. CONVERTIBLE NOTES PAYABLE In September 2022, in connection with the closing of the IPO, the Company converted approximately $ 10.6 2,533,964 From August 2018 through July 2020, the Company issued a total of $ 5.0 2.6 5.0 70 6.62 December 31, 2020 8 The Company obtained the necessary noteholder approvals to extend the maturity date of the notes in November 2021 to May 31, 2022, and in May 2022 to August 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date from August 31, 2022, to October 31, 2022 for certain bridge notes in exchange for a Common Stock purchase warrant equal to the principal amount of each note divided by 10.5 478,446 5.25 From October 2020 through June 2021, the Company issued a total of $ 1.0 0.4 5.0 80 6.62 8 October 2021 The Company obtained the necessary noteholder approvals to extend the maturity date of the notes in December 2021 to May 2022 and in May 2022 to August 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date from August 31, 2022, to October 31, 2022 for certain bridge notes in exchange for a Common Stock purchase warrant equal to the principal amount of each note divided by 10.5 79,795 5.25 0.9 100,000 In the second and third quarters of 2021, the Company issued a total of approximately $ 0.9 0.1 5.0 80 6.62 December 2022 8 Bridge Notes In the fourth quarter of 2021 and the first quarter of 2022, the Company issued a total of $ 2.6 4.20 6 May 31, 2022 In May 2022, the Company obtained the necessary noteholder approvals to extend the maturity date of the notes to August 31, 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date to October 31, 2022, for certain bridge notes in exchange for a Common Stock purchase warrant equal to principal amount of the note divided by 10.5. 199,986 5.25 2.3 175,000 Additionally, each noteholder received a warrant to purchase one share of Common Stock based on the investor’s bridge note principal balance investment. The warrants have a five-year 5.25 9 issued our placement agent a warrant to purchase 29,464 The Company elected to account for the convertible notes payable at fair value with any changes in fair value being recognized through the consolidated statements of operations until the convertible notes are settled. The fair value of the convertible notes was determined with the assistance of a third-party specialist, considering the value of the notes payable that would be received by converting into common stock in each scenario, plus a put option. In coordination with the Company’s IPO, the notes were converted to Common Stock. Convertible notes payable consisted of the following at December 31, 2021: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2022 December 31, 2021 Secured convertible notes payable $ 5,041,957 $ 5,041,957 Unsecured convertible notes payable 4,364,000 3,740,000 Principal amount of convertible notes payable 9,405,957 8,781,957 Debt issuance costs — (1,185,382 ) Fair value adjustments on convertible notes payable 5,422,498 3,555,576 Conversion on IPO (14,503,455 ) 3,555,576 Total convertible notes payable $ 325,000 $ 11,152,151

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	Note 8. FAIR VALUE MEASUREMENTS The Company analyzes all financial instruments with features of both liabilities and equity under the FASB accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid and other expenses, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The table below summarizes the Company’s assets and liabilities that are measured at fair value at September 30, 2022 and December 31, 2021, respectively: SCHEDULE OF FAIR VALUE INSTRUMENTS Fair value measured at September 30, 2022 Total at Using Quoted Using Using Convertible notes payable $ 325,000 $ — $ 325,000 $ — Fair value measured at December 31, 2021 Total at Using Quoted Using Using Convertible notes payable $ 11,152,151 $ — $ — $ 11,152,151 A description of the valuation techniques and the values used for significant unobservable inputs to derive fair value measurements for those assets and liabilities measured at fair value at and December 31, 2021: SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES Fair Value Valuation Technique Unobservable Input Range (Weighted Average) Convertible notes payable at December 31, 2021 $ 11,152,151 Risky Put + Stock Payoff Probability weighting assigned to automatic and optional conversion scenarios 90 10 % Applied discount rate 79.1 % Common share class volatility 46.1 % Preferred stock class volatility 3.9 % Negotiation discount 1.6 % The Company transferred $ 325,000 0.7 0.5 SCHEDULE OF CHANGE IN FAIR VALUE Fair value of convertible notes payable at December 31, 2021 $ 11,152,151 Additional convertible notes payable issued 724,000 Repayment of convertible notes payable (100,000 ) Debt discount for warrants issued (787,566 ) Accretion of debt issuance costs 1,972,948 Change in fair value of convertible notes payable 1,866,922 Transfer from level 3 to level 2 (325,000 ) Conversion of convertible notes payable (14,503,455 ) Fair value of convertible notes payable at September 30, 2022 (Unaudited) $ — Fair value of convertible notes payable at December 31, 2020 $ 9,767,461 Additional convertible notes payable issued 3,295,000 Debt discount for warrants issued (1,665,956 ) Accretion of debt issuance costs 480,574 Change in fair value of convertible notes payable (724,928 ) Fair value of convertible notes payable at December 31, 2021 $ 11,152,151

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 9. COMMITMENTS AND CONTINGENCIES Operating Leases The Company leases its corporate offices under an agreement that is renewable on September 1, 2023. The Company leases its laboratory and additional office space under an operating lease that is renewable annually by written notice by the Company and will require renewal in February 2023. Rent expense for office and lab space amounted to approximately $ 15,000 13,000 41,000 39,000 Legal Matters From time to time, the Company is involved in various disputes and litigation matters that arise in the ordinary course of business. To date, the Company had no material pending legal proceedings.

CONVERTIBLE PREFERRED STOCK AND

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT	Note 10. CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT In June 2022, the Company completed a 1-for-7 reverse stock split 0.007 Convertible Preferred Stock The Company has authorized a total of 20,000,000 0.001 5,296,044 1.3 1.5 4.0 2.6 In accordance with the Certificate of Designation of the Series A Preferred Stock, all of the shares of Series A Preferred Stock that were issued and outstanding at the time of the IPO Closing were automatically converted into 745,558 1-for-7 reverse stock split no Common Stock The Company has authorized a total of 14,285,714 0.007 7,142,857 14,285,714 8,369,750

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	Note 11. STOCK-BASED COMPENSATION The Company grants options under its 2014 Equity Incentive Plan (the “Plan”). Under the Plan, the Company is authorized to grant options for up to 1.1 1.0 The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations: SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS Nine Months Ended 2022 2021 Research and development $ 3,318 $ 12,094 General and administrative 208,427 120,437 Total $ 211,745 $ 132,531 The following table summarizes stock option activity under the Plan: SUMMARY OF OPTION ACTIVITY Number of Weighted-average Weighted-average Aggregate Outstanding at December 31, 2021 878,380 $ 4.12 Granted 7,142 4.20 Exercised (64,848 ) 1.16 Forfeited (14,282 ) 5.95 Outstanding at September 30, 2022 806,392 $ 4.33 4.3 $ 647,793 Vested and exercisable at September 30, 2022 787,746 $ 4.31 4.1 $ 647,793 As of September 30, 2022, there was no 64,848 75,000 no During the nine months ended September 30, 2022, the Company issued options to purchase 7,142 2.84 During the nine months ended September 30, 2022, the Company issued restricted stock units (RSUs) for 14,999 21,000 During the nine months ended September 30, 2021, the Company issued options to purchase 29,279 11,752 1.85 The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2022 and 2021, respectively: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2022 2021 Fair value of Common Stock $ 4.62 $ 3.08 Volatility 63.9 % 88.1 % Expected term (years) 6.0 6.2 Risk-free interest rate 2.20 % 0.92 % Dividend yield 0 % 0 %

WARRANTS

WARRANTS	9 Months Ended
	Sep. 30, 2022
Warrants
WARRANTS	Note 12. WARRANTS We account for Common Stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. Warrants are accounted for as derivative liabilities if the warrants allow for cash settlement or provide for modification of the warrant exercise price in the event subsequent sales of Common Stock by the Company are at a lower price per share than the then-current warrant exercise price. We classify derivative warrant liabilities on the condensed consolidated balance sheet at fair value, and changes in fair value during the periods presented in the condensed consolidated statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. During the nine months ended September 30, 2022, 1,036,486 7.7 In September 2022, in connection with our IPO, we issued a total of 1,282,600 7.35 1,282,600 7.656 Pursuant to the underwriting agreement dated August 31, 2022 (the “Underwriting Agreement”) between the Company and WallachBeth Capital, LLC, as representative of the underwriters (the “Underwriters”), and solely for purposes of covering any over-allotments made in connection with our IPO, we granted the Underwriters an option to purchase up to an additional 192,390 shares of Common Stock at the Offering Price per Unit less $0.02, and/or up to 192,390 Tradeable Warrants at $0.01 per Tradeable Warrant, and/or up to 192,390 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination of additional shares of Common Stock, Tradeable Warrants, and Non-tradeable Warrants representing, in the aggregate, up to 15% of the number of Units sold in the IPO (the “Over-Allotment Option”). The Over-Allotment Option was exercisable for a period of 45 days from the date of our Final Prospectus. 110,167 0.01 110,167 0.01 In 2022, the Company issued $ 724,000 6 5.25 The Company issued an aggregate of 167,557 0.4 2.0 The following table summarizes the calculated aggregate fair values for the warrants using the Black-Scholes method based on the following assumptions at September 30, 2022: SCHEDULE OF FAIR VALUE OF WARRANTS Exercise price per share of warrant $ 5.25 Fair market closing price per share of Common Stock $ 4.13 Volatility 107 121 Expected term (years) 5.0 Risk-free interest rate 1.37 1.62 Dividend yield 0 %

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Note 13. RELATED PARTY TRANSACTIONS Convertible Bridge Promissory Notes On August 11, 2022, certain officers and directors of the Company purchased convertible promissory Bridge Notes from the Company that bore interest at 6 4.20 five 5.25 Zannes Note and Warrant Maria Zannes, the founder, President, Chief Executive Officer, and a director of the Company, purchased a Bridge Note in the principal amount of $ 99,000 23,672 23,571 5.25 Girgenti Note and Warrant Steven Girgenti, the Executive Chairman and a director of the Company, purchased a Bridge Note in the principal amount of $ 150,000 35,866 35,714 5.25

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 14. SUBSEQUENT EVENTS The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements. In October 2022, the Company repaid $ 275,000

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the fair value of the Company’s Common Stock used to measure stock-based compensation for options granted to employees and non-employees; the valuation allowance on the Company’s deferred tax assets; and the fair value of the convertible notes payable.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiary, OncoSelect ®
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly related to the Company’s equity financings, including its IPO, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the financing. The Company capitalized certain legal, accounting and other third-party fees that were directly related to the Company’s IPO. After the completion of the IPO in September 2022, total deferred offering costs of approximately $ 1.8 8,000
Loss Per Share	Loss Per Share Basic earnings (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of Common Shares outstanding during the period. Diluted earnings per share is computed by dividing net income attributable to common stockholders by the sum of the weighted-average number of Common Shares outstanding during the period and the weighted-average number of dilutive Common Share equivalents outstanding during the period, using the treasury stock method. Dilutive Common Share equivalents are comprised of in-the-money stock options, convertible notes payable, and warrants based on the average stock price for each period using the treasury stock method. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2022 and 2021, as they would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES 2022 2021 As of September 30, 2022 2021 Convertible preferred stock — 756,558 Shares underlying options outstanding 806,392 828,386 Shares underlying warrants outstanding 4,624,952 6,428 Shares underlying convertible notes outstanding 83,373 1,591,372 Anti-dilutive securities 5,514,717 3,182,744
Revenue Recognition	Revenue Recognition Our revenue is generated exclusively from royalties for our first diagnostic test, CyPath ® ® To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation.
Reclassifications	Reclassifications Certain prior year balances have been reclassified to conform to current year presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistency in application. ASU 2019-12 will be effective for public entities for interim and annual periods beginning after December 15, 2020, with early adoption permitted. The Company adopted ASU 2019-12 and concluded there is no impact on the Company’s consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. By removing the separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded conversion features. This new standard also removes certain settlement conditions that are required for contracts to qualify for equity classification and simplifies the diluted earnings per share calculations by requiring that an entity use the if-converted method and that the effect of potential share settlement be included in diluted earnings per share calculations. The new standard will be effective for fiscal years beginning after December 15, 2023 for smaller reporting companies. The Company has not yet determined the potential impact the adoption may have on our consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES	The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of September 30, 2022 and 2021, as they would be anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES 2022 2021 As of September 30, 2022 2021 Convertible preferred stock — 756,558 Shares underlying options outstanding 806,392 828,386 Shares underlying warrants outstanding 4,624,952 6,428 Shares underlying convertible notes outstanding 83,373 1,591,372 Anti-dilutive securities 5,514,717 3,182,744

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Prepaid Expenses And Other Current Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets are summarized below: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, 2022 December 31, 2021 Insurance $ 471,270 $ 16,765 Legal and professional 61,219 55,081 Other 8,834 4,219 Total prepaid expenses and other current assets $ 541,323 $ 76,065

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment are summarized below: SCHEDULE OF PROPERTY AND EQUIPMENT September 30, 2022 December 31, 2021 Lab equipment $ 242,168 $ 242,168 Computers and software 21,463 21,463 Property and equipment, gross 263,631 263,631 Accumulated depreciation (261,850 ) (258,998 ) Total property and equipment, net $ 1,781 $ 4,633

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses are summarized below: SCHEDULE OF ACCRUED EXPENSES September 30, 2022 December 31, 2021 Compensation $ 231,628 $ 277,185 Legal and professional 188,524 166,069 Clinical 49,630 39,482 Other 4,253 765 Total accrued expenses $ 474,035 $ 483,501

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	The Company elected to account for the convertible notes payable at fair value with any changes in fair value being recognized through the consolidated statements of operations until the convertible notes are settled. The fair value of the convertible notes was determined with the assistance of a third-party specialist, considering the value of the notes payable that would be received by converting into common stock in each scenario, plus a put option. In coordination with the Company’s IPO, the notes were converted to Common Stock. Convertible notes payable consisted of the following at December 31, 2021: SCHEDULE OF CONVERTIBLE NOTES PAYABLE September 30, 2022 December 31, 2021 Secured convertible notes payable $ 5,041,957 $ 5,041,957 Unsecured convertible notes payable 4,364,000 3,740,000 Principal amount of convertible notes payable 9,405,957 8,781,957 Debt issuance costs — (1,185,382 ) Fair value adjustments on convertible notes payable 5,422,498 3,555,576 Conversion on IPO (14,503,455 ) 3,555,576 Total convertible notes payable $ 325,000 $ 11,152,151

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE INSTRUMENTS	SCHEDULE OF FAIR VALUE INSTRUMENTS Fair value measured at September 30, 2022 Total at Using Quoted Using Using Convertible notes payable $ 325,000 $ — $ 325,000 $ — Fair value measured at December 31, 2021 Total at Using Quoted Using Using Convertible notes payable $ 11,152,151 $ — $ — $ 11,152,151
SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES	SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES Fair Value Valuation Technique Unobservable Input Range (Weighted Average) Convertible notes payable at December 31, 2021 $ 11,152,151 Risky Put + Stock Payoff Probability weighting assigned to automatic and optional conversion scenarios 90 10 % Applied discount rate 79.1 % Common share class volatility 46.1 % Preferred stock class volatility 3.9 % Negotiation discount 1.6 %
SCHEDULE OF CHANGE IN FAIR VALUE	SCHEDULE OF CHANGE IN FAIR VALUE Fair value of convertible notes payable at December 31, 2021 $ 11,152,151 Additional convertible notes payable issued 724,000 Repayment of convertible notes payable (100,000 ) Debt discount for warrants issued (787,566 ) Accretion of debt issuance costs 1,972,948 Change in fair value of convertible notes payable 1,866,922 Transfer from level 3 to level 2 (325,000 ) Conversion of convertible notes payable (14,503,455 ) Fair value of convertible notes payable at September 30, 2022 (Unaudited) $ — Fair value of convertible notes payable at December 31, 2020 $ 9,767,461 Additional convertible notes payable issued 3,295,000 Debt discount for warrants issued (1,665,956 ) Accretion of debt issuance costs 480,574 Change in fair value of convertible notes payable (724,928 ) Fair value of convertible notes payable at December 31, 2021 $ 11,152,151

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS	The Company has recorded stock-based compensation expense (credit) related to the issuance of stock option awards in the following line items in the accompanying condensed consolidated statement of operations: SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS Nine Months Ended 2022 2021 Research and development $ 3,318 $ 12,094 General and administrative 208,427 120,437 Total $ 211,745 $ 132,531
SUMMARY OF OPTION ACTIVITY	The following table summarizes stock option activity under the Plan: SUMMARY OF OPTION ACTIVITY Number of Weighted-average Weighted-average Aggregate Outstanding at December 31, 2021 878,380 $ 4.12 Granted 7,142 4.20 Exercised (64,848 ) 1.16 Forfeited (14,282 ) 5.95 Outstanding at September 30, 2022 806,392 $ 4.33 4.3 $ 647,793 Vested and exercisable at September 30, 2022 787,746 $ 4.31 4.1 $ 647,793
SCHEDULE OF FAIR VALUE ASSUMPTIONS	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2022 and 2021, respectively: SCHEDULE OF FAIR VALUE ASSUMPTIONS 2022 2021 Fair value of Common Stock $ 4.62 $ 3.08 Volatility 63.9 % 88.1 % Expected term (years) 6.0 6.2 Risk-free interest rate 2.20 % 0.92 % Dividend yield 0 % 0 %

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2022
Warrants
SCHEDULE OF FAIR VALUE OF WARRANTS	The following table summarizes the calculated aggregate fair values for the warrants using the Black-Scholes method based on the following assumptions at September 30, 2022: SCHEDULE OF FAIR VALUE OF WARRANTS Exercise price per share of warrant $ 5.25 Fair market closing price per share of Common Stock $ 4.13 Volatility 107 121 Expected term (years) 5.0 Risk-free interest rate 1.37 1.62 Dividend yield 0 %

NATURE OF OPERATIONS, ORGANIZ_2

NATURE OF OPERATIONS, ORGANIZATION, AND BASIS OF PRESENTATION (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Sep. 06, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Aug. 11, 2022	Dec. 31, 2021
Common stock par value		$ 0.007	$ 0.007	$ 0.007		$ 0.007
Warrant exercise price					$ 5.25
Reverse stock split			1-for-7 reverse stock split
Accumulated deficit		$ 34,992,885		$ 34,992,885		$ 28,513,355
Cash and cash equivalents		$ 13,497,938		$ 13,497,938		$ 1,360,638
Total assets, percent		96%		96%
Tradeable Warrant [Member]
Warrant exercise price		$ 7.35		$ 7.35
Non Tradeable Warrant [Member]
Warrant exercise price		$ 7.656		$ 7.656
Common Stock [Member]
Stock issued during period, shares				1,282,600
IPO [Member]
Stock issued during period, shares	1,282,600
Offering price, per share	$ 6.125
Initial public offering, description	Each Unit consists of (i) one share of the Company’s common stock, par value $0.007 per share (“Common Stock”), (ii) one tradeable warrant (a “Tradeable Warrant”) exercisable for the purchase of one share of Common Stock at an exercise price of $7.35 per share, and (iii) one non-tradeable warrant (a “Non-tradeable Warrant”) exercisable for the purchase of one share of Common Stock at an exercise price of $7.656 per share
Common stock par value	$ 0.007
Gross proceeds before underwriting discounts, commissions and offering expenses	$ 7,800,000
Convertible notes converted amount	$ 10,600,000	$ 10,600,000
Number of shares issued in debt conversion	2,533,964	2,533,964
IPO [Member] | Convertible Preferred Stock [Member]
Number of shares converted	5,296,044
IPO [Member] | Tradeable Warrant [Member]
Warrant exercise price	$ 7.35
IPO [Member] | Non Tradeable Warrant [Member]
Warrant exercise price	$ 7.656
IPO [Member] | Common Stock [Member]
Number of shares issued during conversion	756,558

SCHEDULE OF POTENTIALLY DILUTIV

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	5,514,717	3,182,744
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		756,558
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	806,392	828,386
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	4,624,952	6,428
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	83,373	1,591,372

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Deferred offering costs	$ 1,800,000	$ 8,000

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Insurance	$ 471,270	$ 16,765
Legal and professional	61,219	55,081
Other	8,834	4,219
Total prepaid expenses and other current assets	$ 541,323	$ 76,065

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 263,631	$ 263,631
Accumulated depreciation	(261,850)	(258,998)
Total property and equipment, net	1,781	4,633
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	242,168	242,168
Computer and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 21,463	$ 21,463

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 800	$ 1,200	$ 2,900	$ 4,000

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Compensation	$ 231,628	$ 277,185
Legal and professional	188,524	166,069
Clinical	49,630	39,482
Other	4,253	765
Total accrued expenses	$ 474,035	$ 483,501

LOAN PAYABLE (Details Narrative

LOAN PAYABLE (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2022	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Short-Term Debt [Line Items]
Loan payable	$ 490,117		$ 490,117		$ 490,117
Gain on extinguishment of debt					212,258	$ 239,200
PPP Loan [Member]
Short-Term Debt [Line Items]
Loan payable		$ 200,000
Loan interest rate		1%
Loan maturity term		2 years
Gain on extinguishment of debt					200,000	$ 200,000
Short-Term Debt [Member]
Short-Term Debt [Line Items]
Loan payable	$ 500,000		$ 500,000		$ 500,000
Loan interest rate	4.30%		4.30%		4.30%
Loan payment term	ten monthly payments
Loan periodic payment amount	$ 42,000

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Principal amount of convertible notes payable	$ 9,405,957	$ 8,781,957
Debt issuance costs		(1,185,382)
Fair value adjustments on convertible notes payable	5,422,498	3,555,576
Conversion on IPO	(14,503,455)	3,555,576
Total convertible notes payable	325,000	11,152,151
Secured Debt [Member]
Short-Term Debt [Line Items]
Principal amount of convertible notes payable	5,041,957	5,041,957
Unsecured Debt [Member]
Short-Term Debt [Line Items]
Principal amount of convertible notes payable	$ 4,364,000	$ 3,740,000

CONVERTIBLE NOTES PAYABLE (Deta

CONVERTIBLE NOTES PAYABLE (Details Narrative)		1 Months Ended		3 Months Ended				9 Months Ended			24 Months Ended
	Sep. 06, 2022 USD ($) shares	Oct. 31, 2022 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Sep. 30, 2021 USD ($) $ / shares	Jun. 30, 2021 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) $ / shares	Jun. 30, 2021 USD ($) $ / shares shares	Jul. 31, 2020 USD ($) $ / shares shares	Aug. 11, 2022 $ / shares
Short-Term Debt [Line Items]
Notes payable			$ 325,000		$ 11,152,151			$ 325,000
Conversion price per share | $ / shares												$ 4.20
Warrants exercise price | $ / shares												$ 5.25
Payment for note not converted								$ 100,000
Subsequent Event [Member]
Short-Term Debt [Line Items]
Payment for note not converted		$ 275,000
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Notes converted amount										$ 900,000
Notes payable							$ 1,000,000			1,000,000	$ 5,000,000
Notes payable to related parties							400,000			400,000	2,600,000
Proceeds from issued and sale of equity						$ 5,000,000	$ 5,000,000			$ 5,000,000	$ 5,000,000
Conversion price percentage						0.80	0.80			0.80	0.70
Conversion price per share | $ / shares						$ 6.62	$ 6.62		$ 6.62	$ 6.62	$ 6.62
Maturity date											Dec. 31, 2020
Interest rate						8%	8%		8%	8%	8%
Maturity date extension description										The Company obtained the necessary noteholder approvals to extend the maturity date of the notes in December 2021 to May 2022 and in May 2022 to August 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date from August 31, 2022, to October 31, 2022 for certain bridge notes in exchange for a Common Stock purchase warrant equal to the principal amount of each note divided by 10.5	The Company obtained the necessary noteholder approvals to extend the maturity date of the notes in November 2021 to May 31, 2022, and in May 2022 to August 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date from August 31, 2022, to October 31, 2022 for certain bridge notes in exchange for a Common Stock purchase warrant equal to the principal amount of each note divided by 10.5
Warrants to purchase common stock | shares							79,795			79,795	478,446
Warrants exercise price | $ / shares							$ 5.25			$ 5.25	$ 5.25
Maturity period						2022-12	2022-12			2021-10
Notes payable						$ 900,000	$ 900,000		$ 900,000	$ 900,000
Notes payable to related parties						$ 100,000	$ 100,000		$ 100,000	$ 100,000
Convertible Notes Payable [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Payment for note not converted		100,000
Bridge Notes [Member]
Short-Term Debt [Line Items]
Notes converted amount					$ 2,300,000
Conversion price per share | $ / shares				$ 4.20	$ 4.20
Maturity date				May 31, 2022	May 31, 2022
Interest rate				6%	6%
Maturity date extension description				In May 2022, the Company obtained the necessary noteholder approvals to extend the maturity date of the notes to August 31, 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date to October 31, 2022, for certain bridge notes in exchange for a Common Stock purchase warrant equal to principal amount of the note divided by 10.5.	In May 2022, the Company obtained the necessary noteholder approvals to extend the maturity date of the notes to August 31, 2022. In July 2022, the Company obtained approval from a majority of the noteholders to extend the maturity date to October 31, 2022, for certain bridge notes in exchange for a Common Stock purchase warrant equal to principal amount of the note divided by 10.5.
Warrants to purchase common stock | shares				199,986
Warrants exercise price | $ / shares			$ 5.25	$ 5.25				$ 5.25
Notes payable				$ 2,600,000	$ 2,600,000
Warrants term			5 years					5 years
Bridge Notes [Member] | Placement Agent [Member]
Short-Term Debt [Line Items]
Warrants to purchase common stock | shares			29,464					29,464
Commission percentage			9%					9%
Bridge Notes [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Payment for note not converted		$ 175,000
IPO [Member]
Short-Term Debt [Line Items]
Notes converted amount	$ 10,600,000		$ 10,600,000
Number of shares issued in debt conversion | shares	2,533,964		2,533,964

SCHEDULE OF FAIR VALUE INSTRUME

SCHEDULE OF FAIR VALUE INSTRUMENTS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 325,000	$ 11,152,151
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	325,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable		$ 11,152,151

SCHEDULE OF FAIR VALUE ASSETS A

SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 11,152,151
Applied Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	79.10%
Common Share Class Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	46.10%
Preferred Stock Class Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	3.90%
Negotiation Discount [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	1.60%
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	90%
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Weighted average	10%

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value of convertible notes payable at December 31, 2021	$ 11,152,151	$ 9,767,461
Additional convertible notes payable issued	724,000	3,295,000
Repayment of convertible notes payable	(100,000)
Accretion of debt issuance costs	(787,566)	(1,665,956)
Accretion of debt issuance costs	1,972,948	480,574
Change in fair value of convertible notes payable	1,866,922	(724,928)
Transfer from level 3 to level 2	(325,000)
Conversion of convertible notes payable	(14,503,455)
Fair value of convertible notes payable at September 30, 2022 (Unaudited)		$ 11,152,151

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible debt	$ 700,000	$ 500,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible notes payable	$ 325,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 15,000	$ 13,000	$ 41,000	$ 39,000

CONVERTIBLE PREFERRED STOCK A_2

CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	1 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Jul. 31, 2017	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Nov. 30, 2021
Class of Stock [Line Items]
Reverse stock split		1-for-7 reverse stock split
Common stock, par value	$ 0.007	$ 0.007		$ 0.007		$ 0.007
Preferred stock, shares authorized	20,000,000			20,000,000
Preferred stock par value	$ 0.001			$ 0.001
Proceeds from issuance of private placement	0			0		0
Net proceeds				$ 6,027,414
Preferred stock, shares outstanding	0			0		0
Common stock, shares authorized	14,285,714			14,285,714		14,285,714
Common stock, shares issued	8,369,750			8,369,750		2,677,140
Minimum [Member]
Class of Stock [Line Items]
Common stock, shares authorized							7,142,857
Maximum [Member]
Class of Stock [Line Items]
Common stock, shares authorized							14,285,714
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from issuance of private placement			1,300,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Reverse stock split			1-for-7 reverse stock split
Proceeds from issuance of private placement	5,296,044		4,000,000	5,296,044
Net proceeds			$ 1,500,000
Shares issued for exchange of notes payable and accrued interest			$ 2,600,000
Number of shares issued in debt conversion	745,558

SUMMARY OF STOCK-BASED COMPENSA

SUMMARY OF STOCK-BASED COMPENSATION EXPENSE RECOGNIZED FOR STOCK OPTION AWARDS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 211,745	$ 132,531
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	3,318	12,094
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 208,427	$ 120,437

SUMMARY OF OPTION ACTIVITY (Det

SUMMARY OF OPTION ACTIVITY (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Options Outstanding, beginning balance	878,380
Weighted-Average Exercise Price Outstanding, beginning balance	$ 4.12
Options Granted	7,142	29,279
Weighted-Average Exercise Price, Granted	$ 4.20
Options Exercised	(64,848)	0
Weighted-Average Exercise Price, Exercised	$ 1.16
Options, Forfeited	(14,282)
Weighted-Average Exercise Price,Forfeited	$ 5.95
Options Outstanding, ending balance	806,392
Weighted-Average Exercise Price Outstanding, ending balance	$ 4.33
Weighted- Average Remaining Contractual Term, Outstanding	4 years 3 months 18 days
Aggregate Intrinsic Value Outstanding, ending balance	$ 647,793
Options, Vested and exercisable	787,746
Weighted-Average Exercise Price, Vested and exercisable	$ 4.31
Weighted- Average Remaining Contractual Term, Vested and exercisable	4 years 1 month 6 days
Aggregate Intrinsic Value, Vested and exercisable	$ 647,793

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Fair value of Common Stock	$ 4.62	$ 3.08
Volatility	63.90%	88.10%
Expected term (in years)	6 years	6 years 2 months 12 days
Risk-free interest rate	220%	92%
Dividend yield	0%	0%

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant option, outstanding	1,100,000	1,100,000
Shares reserved		1,000,000
Unrecognized compensation	$ 0	$ 0
Options exercised, shares		64,848	0
Options exercised, value	$ 74,900	$ 75,000
Grant date fair value of options granted		7,142	29,279
Weighted-average grant date fair value of options granted		$ 2.84	$ 1.85
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant date fair value of options granted		14,999	11,752
Shares vested		21,000

SCHEDULE OF FAIR VALUE OF WARRA

SCHEDULE OF FAIR VALUE OF WARRANTS (Details)	Sep. 30, 2022 $ / shares	Aug. 11, 2022 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price		$ 5.25
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 5.25
Warrants rights and outstadning measurement	4.13
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants rights and outstadning measurement	1.37
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants rights and outstadning measurement	1.62
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants rights and outstadning measurement	107
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants rights and outstadning measurement	121
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term (years)	5 years
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants rights and outstadning measurement	0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 31, 2022	Sep. 30, 2022	Aug. 11, 2022
Exercise price			$ 5.25
Class of warrant description	Pursuant to the underwriting agreement dated August 31, 2022 (the “Underwriting Agreement”) between the Company and WallachBeth Capital, LLC, as representative of the underwriters (the “Underwriters”), and solely for purposes of covering any over-allotments made in connection with our IPO, we granted the Underwriters an option to purchase up to an additional 192,390 shares of Common Stock at the Offering Price per Unit less $0.02, and/or up to 192,390 Tradeable Warrants at $0.01 per Tradeable Warrant, and/or up to 192,390 Non-tradeable Warrants at $0.01 per Non-tradeable Warrant, or any combination of additional shares of Common Stock, Tradeable Warrants, and Non-tradeable Warrants representing, in the aggregate, up to 15% of the number of Units sold in the IPO (the “Over-Allotment Option”). The Over-Allotment Option was exercisable for a period of 45 days from the date of our Final Prospectus.
Beneficial conversion feature		$ 400,000
Interest expense		2,000,000
Bridge Notes [Member]
Stock issued for conversion of debt, value		$ 724,000
Accrued interest rate		6%
Aggregate warrants		$ 167,557
Warrant [Member]
Warrants issued		1,036,486
Net proceeds from direct offering costs		$ 7,700,000
Warrant [Member] | Bridge Notes [Member]
Exercise price		$ 5.25
Tradeable Warrant [Member]
Warrants issued		1,282,600
Exercise price		$ 7.35
Tradeable Warrant [Member] | Over-Allotment Option [Member]
Warrants issued		110,167
Exercise price		$ 0.01
Non Tradeable Warrant [Member]
Warrants issued		1,282,600
Exercise price		$ 7.656
Non Tradeable Warrant [Member] | Over-Allotment Option [Member]
Warrants issued		110,167
Exercise price		$ 0.01

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			9 Months Ended
	Aug. 11, 2022	Aug. 11, 2022	Sep. 30, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt conversion rate		6%
Conversion of debt price per share	$ 4.20	$ 4.20
Conversion term	5 years
Warrants exercise price	$ 5.25	$ 5.25
Principal amount			$ 9,405,957	$ 8,781,957
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Warrants exercise price			$ 5.25
Principal amount			$ 99,000
Converted common stock			23,672
Warrants to purchase common stock			23,571
Steven Girgenti [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Warrants exercise price			$ 5.25
Principal amount			$ 150,000
Converted common stock			35,866
Warrants to purchase common stock			35,714

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Oct. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Repayments of convertible debt		$ 100,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Repayments of convertible debt	$ 275,000